Alpha-GPC: Evidence, Label Amounts and EU Status

Alpha-GPC at a glance

Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline compound. Choline is the raw material for acetylcholine, the messenger behind muscle contraction, memory and attention. In small trials in young men, alpha-GPC raised lower-body isometric force after six days and improved one of three cognitive tests after a single dose. Most other measures did not change. It is the active substance of medicines in Italy and Poland, and the EU novel food catalogue lists it as not yet authorised.

Evidence: Human trials · Updated 20 November 2026

What alpha-GPC is

Alpha-GPC is short for L-alpha-glycerylphosphorylcholine, a phospholipid that contains choline. Medicines list the same compound as choline alfoscerate. It was authorised as a medicine in 1985, and today it is sold both as a medicine and as a supplement ingredient.

Choline is an essential nutrient. The body needs it for normal cell function and uses it to make acetylcholine. All four Hammer Labz panels below list the ingredient as “Alpha GPC”.

How it works

Acetylcholine carries the signal from nerve to muscle fibre, and in the brain it takes part in memory and attention. The body builds it from choline, and alpha-GPC is one way of supplying choline.

In eight healthy young men, a single 1,000 mg dose raised blood free choline at 60 and 120 minutes. In a trial in 48 college-aged men, serum free choline after the first dose was 132% higher with 500 mg and 59% higher with 250 mg than with placebo. In rats, alpha-GPC increased the release of acetylcholine in the hippocampus, a brain area involved in learning and memory.

These steps show where alpha-GPC can act. They do not show how much acetylcholine a serving adds in a trained person’s muscles or brain. Huperzine A works on the same system from the other end: it slows the enzyme that breaks acetylcholine down.

Evidence

Evidence label: Human trials. Our labels describe the ingredient, not a product; see how we review.

Strength and power. In a crossover trial, 13 college-aged men took 600 mg of alpha-GPC a day or placebo for six days. Peak force in the isometric mid-thigh pull rose by 98.8 N on alpha-GPC and fell by 39.0 N on placebo. Upper-body force moved the same way, but the difference was not statistically significant.

A 2017 trial randomised 48 healthy college-aged men to 250 mg or 500 mg of alpha-GPC, 200 mg of caffeine or placebo daily for seven days. Isometric strength and a reaction-time test did not differ between the groups. In the countermovement jump, the 250 mg group showed the largest gains in maximum velocity and power. Thyroid-stimulating hormone was lower in the 500 mg group than in the other groups.

Focus. In a 2024 crossover trial, 20 resistance-trained men took 315 mg or 630 mg of alpha-GPC or placebo once, an hour before testing. Both doses improved the Stroop test score more than placebo, and the higher dose also cut the time needed to complete it. Two other cognitive tests, jumps, bench press throws and growth hormone after squats did not differ from placebo.

Growth hormone. In the eight young men above, the single 1,000 mg dose raised growth hormone at rest after 60 minutes, while placebo did not. The 2024 trial measured growth hormone after a squat session and found no difference.

Who paid. Each of the three trials in college-aged or trained men was funded, at least in part, by a company that supplies alpha-GPC. Each also used that company’s ingredient: Chemi Nutra’s in the 2015 and 2017 trials, NNB Nutrition’s in the 2024 trial.

Use with care. A South Korean study of health insurance records covered 12 million adults aged 50 and over. People prescribed alpha-GPC in 2006–2008 had a higher risk of stroke from 2009 to 2018 than matched non-users (adjusted hazard ratio 1.43), and the risk rose with longer prescriptions. The study is observational, so it cannot show that alpha-GPC caused the strokes. The authors note that gut bacteria turn choline into TMAO, a compound linked to cardiovascular disease. Check with a doctor first if you have had a stroke, have heart disease or high blood pressure, or take any medication.

Amounts on labels

Amounts per serving on the Hammer Labz panels:

  • Lion Blood: 600 mg per 20 ml (one cap).
  • Fireball Elite: 600 mg per 10 g.
  • Daily Pump: 300 mg per 10 g scoop.
  • Atomic Strength: 300 mg per 10 g scoop.

The trials in healthy men above used 250 to 630 mg, once or daily for six to seven days, and the growth hormone study a single 1,000 mg dose.

Legal and anti-doping status

Status checked on 20 November 2026.

  • EU, food: the EU novel food catalogue lists alpha-GPC (entry “L-alpha glycerylfosforylcholine”) as a novel food that is not yet authorised, for use in food and food supplements. It is not on the Union list of authorised novel foods. Food authorities in Sweden, Poland, Germany, Italy, Spain and other EU countries have reported alpha-GPC in supplements as an unauthorised novel food. Their notifications in RASFF, the EU’s rapid alert system, date from 2021 to 2026.
  • EU, medicines: choline alfoscerate is the active substance of medicines authorised in Italy (Gliatilin, Delecit) and Poland (Gliatilin), in oral and injectable forms, according to the European Medicines Agency’s database. Its status as a medicine there does not make it an authorised food ingredient: in EU food law it remains a novel food without authorisation.
  • WADA: alpha-GPC is not named on the 2026 or 2027 WADA List. If you are a tested athlete, check any supplement with your anti-doping organisation.
  • Not for drug-tested athletes: Lion Blood and Atomic Strength list DMHA, and Atomic Strength also lists DMAA, octopamine and methylsynephrine. Fireball Elite lists ephedra, a plant source of ephedrine. WADA names DMAA, octopamine, oxilofrine (methylsynephrine), ephedrine and octodrine, one of two compounds sold as DMHA, in class S6, prohibited in competition.

Status differs by country and changes over time.

Found in

Hammer Labz (brand page)

  • Lion Blood
  • Fireball Elite
  • Daily Pump
  • Atomic Strength

Haya Labs

  • Haya Alpha GPC (60 capsules)

We have not seen the Haya Labs label, so we give no amount. Lion Blood pairs alpha-GPC with L-theanine and huperzine A.

Sources

  1. Product labels: Hammer Labz supplement facts panels for Lion Blood, Fireball Elite, Daily Pump and Atomic Strength, as listed in November 2026.
  2. Sagaro GG, Traini E, Amenta F (2023). Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis, 92(1), 59–70. PMID: 36683513.
  3. Kerksick CM (2024). Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients, 16(23), 4240. PMID: 39683633.
  4. Kawamura T, Okubo T, Sato K, et al. (2012). Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults. Nutrition, 28(11–12), 1122–1126. PMID: 22673596.
  5. Marcus L, Soileau J, Judge LW, et al. (2017). Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr, 14, 39. PMID: 29042830.
  6. Traini E, Bramanti V, Amenta F (2013). Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res, 10(10), 1070–1079. PMID: 24156263.
  7. Wang R, Yan H, Tang XC (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin, 27(1), 1–26. PMID: 16364207.
  8. Bellar D, LeBlanc NR, Campbell B (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr, 12, 42. PMID: 26582972.
  9. Lee G, Choi S, Chang J, et al. (2021). Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open, 4(11), e2136008. PMID: 34817582. Erratum: JAMA Netw Open, 2026, 9(9), e2639482.
  10. European Commission. EU Novel Food status catalogue, entry “L-alpha glycerylfosforylcholine”. Accessed 20 November 2026.
  11. European Union. Commission Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods. Consolidated text of 10 August 2026. Accessed 20 November 2026.
  12. European Commission. RASFF Window: Rapid Alert System for Food and Feed. Notifications on alpha-GPC in food supplements, 2021–2026. Accessed 20 November 2026.
  13. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 20 November 2026.
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.